Richard D. Pilnik - 07 Apr 2025 Form 4 Insider Report for DiaMedica Therapeutics Inc. (DMAC)

Role
Director
Signature
/s/ Amy Culbert, attorney-in-fact
Issuer symbol
DMAC
Transactions as of
07 Apr 2025
Net transactions value
+$50,640
Form type
4
Filing time
08 Apr 2025, 16:41:36 UTC
Previous filing
03 Jan 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DMAC Voting Common Shares, no par value per share Options Exercise $50,640 +24,000 +8.3% $2.11 312,995 07 Apr 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DMAC Stock Option (right to buy) Options Exercise $0 -24,000 -100% $0.000000 0 07 Apr 2025 Voting Common Shares 24,000 $2.11 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents an exercise price of $3.00 Canadian dollars, converted to U.S. dollars at an exchange rate of CAD$0.7032 to U.S. $1.00 on April 4, 2025.
F2 Includes 7,588 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan and 139,954 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan, as amended from time to time.
F3 This option has fully vested.